|
|
Comprehensive Sterile Compounding Certificate Program
May 8th - 10th, 2025
COMPREHENSIVE STERILE COMPOUNDING is an accredited 3-day, 20-hour (2.0 CEUs) practice-based course designed for pharmacists and technicians who are experienced in compounding.
Physicians and other healthcare professionals are welcome to attend. This course will also provide initial aseptic training for pharmacists and technicians required by their state board of pharmacy to compound sterile preparations.
Participants are instructed in the proper aseptic techniques... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
|
Veterinary Compounding Essentials
June 6th -7th, 2025
VETERINARY COMPOUNDING ESSENTIALS is a 15-hour accredited course (1.5 CEUs) designed for pharmacists, technicians, and marketers. This practice-based program covers essential techniques for growing a veterinary compounding practice, including calculations, safety practices, hands-on compounding, and marketing.
At the conclusion of this course, participants will be able to:
*Understand animal diseases relevant to medication compliance.
*Identify flavoring options f... |
|
|
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided wit... |
|
|
New Guidelines and Novel Treatments for PAH: Taking a Forward-Looking Data Dive Into the Pool of Emerging Therapies
Target Audience
This educational activity has been designed to meet the needs of cardiologists, pulmonologists, rheumatologists, and other physicians, including those in primary care and internal medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with pulmonary arterial hypertension (PAH).
Program Overview
Discoveries about the pathogenesis of pulmonary arterial hypertension (PAH) revealed key mo... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden: A Care Team Forum®
Target Audience
Transplant, infectious disease, internal medicine, nephrologists, primary care, pharmacy clinicians, advanced practice providers, and surgeons managing patients with CMV
Program Overview
Cytomegalovirus (CMV) is one of the most common infectious complications in solid organ transplant (SOT) recipients. During this activity, the faculty will discuss best practices for prevention and treatment of CMV post-transplant and provide clinical pearls for managing difficult-to-tr... |
|
|
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
In this on-demand activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty, Jeanne Palmer, MD and Jennifer Andres, APRN, FNP, MSN as they discuss Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) can optimize clinical outcomes and patient quality of life (QOL).
Gain expe... |
|
|
Navigating the Evolving Standards of Newly Diagnosed Multiple Myeloma Treatment: Exploring the Evidence on New Combination Strategies
ACTIVITY DESCRIPTION
The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation,... |
|
|
Defining the therapeutic algorithm in patients with HR positive breast cancer - United States
Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer
Learning Objectives
Upon completion of this activity, participants should be better able to:
Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globall
Apply the most recent evid... |
|
|
Antibody Drug Conjugates (ADC) - United States
Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globall
Apply the most recent evi... |
|
|
Patient Point of View: PDE4 Inhibitors for the Treatment of Adult Plaque Psoriasis
Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts affected individuals’ quality of life. The most common subtype is plaque psoriasis, characterized by erythematous to violaceous plaques covered with scales. Due to the substantial symptom burden of plaque psoriasis and challenges surrounding medication tolerability and adherence, innovative treatment options are needed. Phosphodiesterase-4 (PDE4) inhibitors, which play a key role in the inflammatory... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Toxicity Management and Symptom Control in Advanced RCC: Playbook Update
STATEMENT OF NEED
Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standard... |
|
|
New Guidelines, Emerging Treatments, and Unexpected Patients: Understanding the Challenges of PAH
Target Audience
This activity is designed for nurse practitioners, nurses, and physician assistants who manage patients with or at risk for PAH.
Program Overview
It is a deadly disease and there’s still no cure, but with treatment, survival for patients with pulmonary arterial hypertension (PAH) can be significantly extended. Although rare, nurse practitioners are likely to encounter this cardiopulmonary disorder throughout their careers, and need to be familiar with the multiple dru... |
|
|
Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant: A Clinical Forum®
Target Audience
Infectious disease, transplantation, internal medicine, and nephrology clinicians
Program Overview
Cytomegalovirus (CMV) is a prevalent and potentially life-threatening viral infection in transplant recipients. CMV management in this high-risk population continues to evolve with updated guidelines and newer, less toxic antiviral therapy.
During this activity, faculty will discuss state-of-the-art strategies for preventing and treating CMV in transplant patients, sharing... |
|
|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |
|
|
WEBINAR: Introduction to Homeopathic Medicines for Veterinary Pharmacists
Overview " Homeopathic medicines have been used for over 200 years in humans, plants, and animals. They have been recognized as drugs by the FDA since 1938 and are easily accessible over-the-counter in all markets. The use of homeopathic medicines continues to grow in popularity, yet many misconceptions still circulate about their efficacy and safety. Many pharmacists lack training on homeopathic medicines, but pharmacists have an obligation to be well-informed about the strengths and lim... |
|
|
WEBINAR: Intro to Anatomy and Physiology and Drug Disposition for Nonhumans
Overview: On March 15, 2021, APhA HOD approved ACVP’s proposal to expand the definition of a “patient” to include both human and non-human species. While this expansion highlights the wide scope of care provided by pharmacists, a paucity in veterinary pharmacotherapy education remains. In two independent surveys, 77% of pharmacists reported that they routinely filled prescriptions for animals. In a 2021, only 26.7% of colleges and schools of pharmacy surveyed responded that veterinary p... |
|